









Markets
/
Stocks
/
nasdaq-arct
/

Arcturus Therapeutics Holdings Inc

ARCT

19.620USD

+1.570+8.70%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

532.64MMarket Cap

LossP/E TTM



Arcturus Therapeutics Holdings Inc

19.620

+1.570+8.70%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

11 / 506

Overall Ranking

76 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

64.778

Target Price

+258.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Undervalued

The company’s latest PE is -8.84, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 26.78M shares, decreasing 12.22% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.81M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.56.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 28.30M, representing a year-over-year decrease of 43.24%, while its net profit experienced a year-over-year decrease of 46.68%.

Score

Industry at a Glance

Previous score

8.40

Change



Financials

9.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.99

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.35

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -8.13, which is -173.11% below the recent high of 5.94 and 10.46% above the recent low of -7.28.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.91, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Arcturus Therapeutics Holdings Inc is 54.00, with a high of 140.00 and a low of 42.00.

Score

Industry at a Glance

Previous score

8.91

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

64.778

Target Price

+258.88%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Arcturus Therapeutics Holdings Inc

ARCT

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 7.16, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 19.64 and the support level at 16.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.16

Change

1.99

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.028

Buy

RSI(14)

67.569

Neutral

STOCH(KDJ)(9,3,3)

77.415

Buy

ATR(14)

1.140

High Vlolatility

CCI(14)

193.460

Buy

Williams %R

1.989

Overbought

TRIX(12,20)

0.612

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

18.242

Buy

MA10

18.087

Buy

MA20

17.718

Buy

MA50

15.677

Buy

MA100

14.111

Buy

MA200

14.642

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 98.75%, representing a quarter-over-quarter decrease of 3.53%. The largest institutional shareholder is The Vanguard, holding a total of 1.81M shares, representing 6.67% of shares outstanding, with 7.53% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

4.69M

BlackRock Institutional Trust Company, N.A.

2.12M

-1.39%

Amova Asset Management Co., Ltd.

1.93M

-6.73%

The Vanguard Group, Inc.

Star Investors

1.74M

+3.83%

ARK Investment Management LLC

Star Investors

2.01M

+3.86%

Payne (Joseph E)

1.48M

State Street Global Advisors (US)

1.28M

-3.45%

Balyasny Asset Management LP

938.19K

+70.97%

Schonfeld Strategic Advisors LLC

825.77K

-2.75%

Woodline Partners LP

780.44K

-3.28%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.13, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.